Search

Your search keyword '"Brust, James C. M."' showing total 194 results
Start Over Author "Brust, James C. M."

Refine your results

more »

more »

more »

more »
194 results on '"Brust, James C. M."'

1. Brief Report: Differentiated Service Delivery Framework for People With Multidrug-Resistant Tuberculosis and HIV Coinfection

Author

Reis, Karl, primary, Wolf, Allison, additional, Perumal, Rubeshan, additional, Seepamore, Boitumelo, additional, Guzman, Kevin, additional, Ross, Jesse, additional, Cheung, Ying Kuen K., additional, Amico, K. Rivet, additional, Brust, James C. M., additional, Padayatchi, Nesri, additional, Friedland, Gerald, additional, Naidoo, Kogieleum, additional, Daftary, Amrita, additional, Zelnick, Jennifer, additional, and O'Donnell, Max, additional

Published
2024
Full Text
View/download PDF

2. Pre-detection history of extensively drug-resistant tuberculosis in KwaZulu-Natal, South Africa

Author

Brown, Tyler S., Challagundla, Lavanya, Baugh, Evan H., Omar, Shaheed Vally, Mustaev, Arkady, Auld, Sara C., Shah, N. Sarita, Kreiswirth, Barry N., Brust, James C. M., Nelson, Kristin N., Narechania, Apurva, Kurepina, Natalia, Mlisana, Koleka, Bonneau, Richard, Eldholm, Vegard, Ismail, Nazir, Kolokotronis, Sergios-Orestis, Robinson, D. Ashley, Gandhi, Neel R., and Mathema, Barun

Published
2019

4. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis

Author

Ahmad, N, Baghaei, P, Barkane, L, Benedetti, A, Brode, SK, Brust, JCM, Campbell, JR, Chang, VWL, Falzon, D, Guglielmetti, L, Isaakidis, P, Kempker, RR, Kipiani, M, Kuksa, L, Lan, Z, Lange, C, Laniado-Laborín, R, Nahid, P, Rodrigues, D, Singla, R, Udwadia, ZF, Menzies, D, Lan, Zhiyi, Ahmad, Nafees, Baghaei, Parvaneh, Barkane, Linda, Benedetti, Andrea, Brode, Sarah K, Brust, James C M, Campbell, Jonathon R, Chang, Vicky Wai Lai, Falzon, Dennis, Guglielmetti, Lorenzo, Isaakidis, Petros, Kempker, Russell R, Kipiani, Maia, Kuksa, Liga, Lange, Christoph, Laniado-Laborín, Rafael, Nahid, Payam, Rodrigues, Denise, Singla, Rupak, Udwadia, Zarir F, and Menzies, Dick

Published
2020
Full Text
View/download PDF

7. Genotype–Phenotype Characterization of Serial Mycobacterium tuberculosis Isolates in Bedaquiline-Resistant Tuberculosis.

Author

Brown, Tyler S, Tang, Linrui, Omar, Shaheed Vally, Joseph, Lavania, Meintjes, Graeme, Maartens, Gary, Wasserman, Sean, Shah, N Sarita, Farhat, Maha R, Gandhi, Neel R, Ismail, Nazir, Brust, James C M, and Mathema, Barun

Subjects
QUINOLINE, SEQUENCE analysis, GENES, GENOTYPES, MYCOBACTERIUM tuberculosis, GENOMICS, RESEARCH funding, PHENOTYPES
Abstract

Background Emerging resistance to bedaquiline (BDQ) threatens to undermine advances in the treatment of drug-resistant tuberculosis (DRTB). Characterizing serial Mycobacterium tuberculosis (Mtb) isolates collected during BDQ-based treatment can provide insights into the etiologies of BDQ resistance in this important group of DRTB patients. Methods We measured mycobacteria growth indicator tube (MGIT)–based BDQ minimum inhibitory concentrations (MICs) of Mtb isolates collected from 195 individuals with no prior BDQ exposure who were receiving BDQ-based treatment for DRTB. We conducted whole-genome sequencing on serial Mtb isolates from all participants who had any isolate with a BDQ MIC >1 collected before or after starting treatment (95 total Mtb isolates from 24 participants). Results Sixteen of 24 participants had BDQ-resistant TB (MGIT MIC ≥4 µg/mL) and 8 had BDQ-intermediate infections (MGIT MIC = 2 µg/mL). Participants with pre-existing resistance outnumbered those with resistance acquired during treatment, and 8 of 24 participants had polyclonal infections. BDQ resistance was observed across multiple Mtb strain types and involved a diverse catalog of mmpR5 (Rv0678) mutations, but no mutations in atpE or pepQ. Nine pairs of participants shared genetically similar isolates separated by <5 single nucleotide polymorphisms, concerning for potential transmitted BDQ resistance. Conclusions BDQ-resistant TB can arise via multiple, overlapping processes, including transmission of strains with pre-existing resistance. Capturing the within-host diversity of these infections could potentially improve clinical diagnosis, population-level surveillance, and molecular diagnostic test development. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Genotype–Phenotype Characterization of Serial Mycobacterium tuberculosis Isolates in Bedaquiline-Resistant Tuberculosis

Author

Brown, Tyler S, primary, Tang, Linrui, additional, Omar, Shaheed Vally, additional, Joseph, Lavania, additional, Meintjes, Graeme, additional, Maartens, Gary, additional, Wasserman, Sean, additional, Shah, N Sarita, additional, Farhat, Maha R, additional, Gandhi, Neel R, additional, Ismail, Nazir, additional, Brust, James C M, additional, and Mathema, Barun, additional

Published
2023
Full Text
View/download PDF

11. Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment

Author

van Beek, Stijn W, primary, Tanneau, Lénaïg, additional, Meintjes, Graeme, additional, Wasserman, Sean, additional, Gandhi, Neel R, additional, Campbell, Angie, additional, Viljoen, Charle A, additional, Wiesner, Lubbe, additional, Aarnoutse, Rob E, additional, Maartens, Gary, additional, Brust, James C M, additional, and Svensson, Elin M, additional

Published
2022
Full Text
View/download PDF

12. Reply to Seddon, Schaaf, and Hesseling

Author

Efficacy Subgroup, RESIST-TB, Dooley, Kelly E., Mitnick, Carole, DeGroote, Mary Ann, Obuku, Ekwaro, Hamilton, Carol D., Makhene, Mamodikoe, Shah, Sarita, Brust, James C. M., Durakovic, Nadza, and Nuermberger, Eric

Published
2013
Full Text
View/download PDF

13. Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment

Author

van Beek, Stijn W., Tanneau, Lénaïg, Meintjes, Graeme, Wasserman, Sean, Gandhi, Neel R., Campbell, Angie, Viljoen, Charle A., Wiesner, Lubbe, Aarnoutse, Rob E., Maartens, Gary, Brust, James C. M., Svensson, Elin, van Beek, Stijn W., Tanneau, Lénaïg, Meintjes, Graeme, Wasserman, Sean, Gandhi, Neel R., Campbell, Angie, Viljoen, Charle A., Wiesner, Lubbe, Aarnoutse, Rob E., Maartens, Gary, Brust, James C. M., and Svensson, Elin

Abstract

Background: The M2 metabolite of bedaquiline causes QT-interval prolongation, making electrocardiogram (ECG) monitoring of patients receiving bedaquiline for drug-resistant tuberculosis necessary. The objective of this study was to determine the relationship between M2 exposure and Fridericia-corrected QT (QTcF)-interval prolongation and to explore suitable ECG monitoring strategies for 6-month bedaquiline treatment. Methods: Data from the PROBeX study, a prospective observational cohort study, were used to characterize the relationship between M2 exposure and QTcF. Established nonlinear mixed-effects models were fitted to pharmacokinetic and ECG data. In a virtual patient population, QTcF values were simulated for scenarios with and without concomitant clofazimine. ECG monitoring strategies to identify patients who need to interrupt treatment (QTcF > 500 ms) were explored. Results: One hundred seventy patients were included, providing 1131 bedaquiline/M2 plasma concentrations and 1702 QTcF measurements; 2.1% of virtual patients receiving concomitant clofazimine had QTcF > 500 ms at any point during treatment (0.7% without concomitant clofazimine). With monthly monitoring, almost all patients with QTcF > 500 ms were identified by week 12; after week 12, patients were predominantly falsely identified as QTcF > 500 ms due to stochastic measurement error. Following a strategy with monitoring before treatment and at weeks 2, 4, 8, and 12 in simulations with concomitant clofazimine, 93.8% of all patients who should interrupt treatment were identified, and 26.4% of all interruptions were unnecessary (92.1% and 32.2%, respectively, without concomitant clofazimine). Conclusions: Our simulations enable an informed decision for a suitable ECG monitoring strategy by weighing the risk of missing patients with QTcF > 500 ms and that of interrupting bedaquiline treatment unnecessarily. We propose ECG monitoring before treatment and at weeks 2, 4, 8, and 12 after st

Published
2022
Full Text
View/download PDF

14. Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa

Author

Haas, David W., Abdelwahab, Mahmoud Tareq, van Beek, Stijn W., Baker, Paxton, Maartens, Gary, Bradford, Yuki, Ritchie, Marylyn D., Wasserman, Sean, Meintjes, Graeme, Beeri, Karen, Gandhi, Neel R., Svensson, Elin, Denti, Paolo, Brust, James C. M., Haas, David W., Abdelwahab, Mahmoud Tareq, van Beek, Stijn W., Baker, Paxton, Maartens, Gary, Bradford, Yuki, Ritchie, Marylyn D., Wasserman, Sean, Meintjes, Graeme, Beeri, Karen, Gandhi, Neel R., Svensson, Elin, Denti, Paolo, and Brust, James C. M.

Abstract

In a cohort of patients treated for drug-resistant tuberculosis in South Africa, CYP3A5*3was associated with slower plasma bedaquiline clearance. Different CYP3A5*3minor allele frequencies among populations may help explain the more rapid bedaquiline clearance previously reported with African ancestry. Background Plasma bedaquiline clearance is reportedly more rapid with African ancestry. Our objective was to determine whether genetic polymorphisms explained between-individual variability in plasma clearance of bedaquiline, its M2 metabolite, and clofazimine in a cohort of patients treated for drug-resistant tuberculosis in South Africa. Methods Plasma clearance was estimated with nonlinear mixed-effects modeling. Associations between pharmacogenetic polymorphisms, genome-wide polymorphisms, and variability in clearance were examined using linear regression models. Results Of 195 cohort participants, 140 were evaluable for genetic associations. Among 21 polymorphisms selected based on prior genome-wide significant associations with any drug, rs776746 (CYP3A5*3) was associated with slower clearance of bedaquiline (P = .0017) but not M2 (P = .25). CYP3A5*3 heterozygosity and homozygosity were associated with 15% and 30% slower bedaquiline clearance, respectively. The lowest P value for clofazimine clearance was with VKORC1 rs9923231 (P = .13). In genome-wide analyses, the lowest P values for clearance of bedaquiline and clofazimine were with RFX4 rs76345012 (P = 6.4 x 10(-7)) and CNTN5 rs75285763 (P = 2.9 x 10(-8)), respectively. Conclusions Among South Africans treated for drug-resistant tuberculosis, CYP3A5*3 was associated with slower bedaquiline clearance. Different CYP3A5*3 frequencies among populations may help explain the more rapid bedaquiline clearance reported in Africans. Associations with RFX4 and CNTN5 are likely by chance alone.

Published
2022
Full Text
View/download PDF

15. Optimized Loading Dose Strategies for Bedaquiline When Restarting Interrupted Drug-Resistant Tuberculosis Treatment

Author

Koele, Simon E., van Beek, Stijn W., Maartens, Gary, Brust, James C. M., Svensson, Elin, Koele, Simon E., van Beek, Stijn W., Maartens, Gary, Brust, James C. M., and Svensson, Elin

Abstract

Interruption of treatment is common in drug-resistant tuberculosis patients. Bedaquiline has a long terminal half-life; therefore, restarting after an interruption without a loading dose could increase the risk of suboptimal treatment outcome and resistance development. Interruption of treatment is common in drug-resistant tuberculosis patients. Bedaquiline has a long terminal half-life; therefore, restarting after an interruption without a loading dose could increase the risk of suboptimal treatment outcome and resistance development. We aimed to identify the most suitable loading dose strategies for bedaquiline restart after an interruption. A model-based simulation study was performed. Pharmacokinetic profiles of bedaquiline and its metabolite M2 (associated with QT prolongation) were simulated for 5,000 virtual patients for different durations and starting points of treatment interruption. Weekly bedaquiline area under the concentration-time curve (AUC) and M2 maximum concentration (C-max) deviation before interruption and after reloading were assessed to evaluate the efficacy and safety, respectively, of the reloading strategies. Bedaquiline weekly AUC and M2 C-max deviation were mainly driven by the duration of interruption and only marginally by the starting point of interruption. For interruptions with a duration shorter than 2 weeks, no new loading dose is needed. For interruptions with durations between 2 weeks and 1 month, 1 month and 1 year, and longer than 1 year, reloading periods of 3 days, 1 week, and 2 weeks, respectively, are recommended. This reloading strategy results in an average bedaquiline AUC deviation of 1.88% to 5.98% compared with -16.4% to -59.8% without reloading for interruptions of 2 weeks and 1 year, respectively, without increasing M2 C-max. This study presents easy-to-implement reloading strategies for restarting a patient on bedaquiline treatment after an interruption.

Published
2022
Full Text
View/download PDF

17. Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis

Author

Bateman, Mark, primary, Wolf, Allison, additional, Chimukangara, Benjamin, additional, Brust, James C M, additional, Lessells, Richard, additional, Amico, Rivet, additional, Boodhram, Resha, additional, Singh, Nalini, additional, Orrell, Catherine, additional, Friedland, Gerald, additional, Naidoo, Kogieleum, additional, Padayatchi, Nesri, additional, and O’Donnell, Max R, additional

Published
2022
Full Text
View/download PDF

20. Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa

Author

Haas, David W, primary, Abdelwahab, Mahmoud Tareq, additional, van Beek, Stijn W, additional, Baker, Paxton, additional, Maartens, Gary, additional, Bradford, Yuki, additional, Ritchie, Marylyn D, additional, Wasserman, Sean, additional, Meintjes, Graeme, additional, Beeri, Karen, additional, Gandhi, Neel R, additional, Svensson, Elin M, additional, Denti, Paolo, additional, and Brust, James C M, additional

Published
2022
Full Text
View/download PDF

22. Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis

Author

Ngwalero, Precious, primary, Brust, James C. M., additional, van Beek, Stijn W., additional, Wasserman, Sean, additional, Maartens, Gary, additional, Meintjes, Graeme, additional, Joubert, Anton, additional, Norman, Jennifer, additional, Castel, Sandra, additional, Gandhi, Neel R., additional, Denti, Paolo, additional, McIlleron, Helen, additional, Svensson, Elin M., additional, and Wiesner, Lubbe, additional

Published
2021
Full Text
View/download PDF

23. TCA cycle remodeling drives proinflammatory signaling in humans with pulmonary tuberculosis

Author

Collins, Jeffrey M., primary, Jones, Dean P., additional, Sharma, Ashish, additional, Khadka, Manoj, additional, Liu, Ken H., additional, Kempker, Russell R., additional, Prideaux, Brendan, additional, Maner-Smith, Kristal, additional, Tukvadze, Nestani, additional, Shah, N. Sarita, additional, Brust, James C. M., additional, Sékaly, Rafick-Pierre, additional, Gandhi, Neel R., additional, Blumberg, Henry M., additional, Ortlund, Eric A., additional, and Ziegler, Thomas R., additional

Published
2021
Full Text
View/download PDF

24. Evidence-based Definition for Extensively Drug-Resistant Tuberculosis

Author

Roelens, Maroussia, primary, Battista Migliori, Giovanni, additional, Rozanova, Liudmila, additional, Estill, Janne, additional, Campbell, Jonathon R., additional, Cegielski, J. Peter, additional, Tiberi, Simon, additional, Palmero, Domingo, additional, Fox, Greg J., additional, Guglielmetti, Lorenzo, additional, Sotgiu, Giovanni, additional, Brust, James C. M., additional, Bang, Didi, additional, Lienhardt, Christian, additional, Lange, Christoph, additional, Menzies, Dick, additional, Keiser, Olivia, additional, and Raviglione, Mario, additional

Published
2021
Full Text
View/download PDF

25. Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment.

Author

Beek, Stijn W van, Tanneau, Lénaïg, Meintjes, Graeme, Wasserman, Sean, Gandhi, Neel R, Campbell, Angie, Viljoen, Charle A, Wiesner, Lubbe, Aarnoutse, Rob E, Maartens, Gary, Brust, James C M, and Svensson, Elin M

Subjects
ELECTROCARDIOGRAPHY, SIMULATED patients, MEASUREMENT errors, PATIENT monitoring, THERAPEUTICS
Abstract

Background The M2 metabolite of bedaquiline causes QT-interval prolongation, making electrocardiogram (ECG) monitoring of patients receiving bedaquiline for drug-resistant tuberculosis necessary. The objective of this study was to determine the relationship between M2 exposure and Fridericia-corrected QT (QTcF)-interval prolongation and to explore suitable ECG monitoring strategies for 6-month bedaquiline treatment. Methods Data from the PROBeX study, a prospective observational cohort study, were used to characterize the relationship between M2 exposure and QTcF. Established nonlinear mixed-effects models were fitted to pharmacokinetic and ECG data. In a virtual patient population, QTcF values were simulated for scenarios with and without concomitant clofazimine. ECG monitoring strategies to identify patients who need to interrupt treatment (QTcF > 500 ms) were explored. Results One hundred seventy patients were included, providing 1131 bedaquiline/M2 plasma concentrations and 1702 QTcF measurements; 2.1% of virtual patients receiving concomitant clofazimine had QTcF > 500 ms at any point during treatment (0.7% without concomitant clofazimine). With monthly monitoring, almost all patients with QTcF > 500 ms were identified by week 12; after week 12, patients were predominantly falsely identified as QTcF > 500 ms due to stochastic measurement error. Following a strategy with monitoring before treatment and at weeks 2, 4, 8, and 12 in simulations with concomitant clofazimine, 93.8% of all patients who should interrupt treatment were identified, and 26.4% of all interruptions were unnecessary (92.1% and 32.2%, respectively, without concomitant clofazimine). Conclusions Our simulations enable an informed decision for a suitable ECG monitoring strategy by weighing the risk of missing patients with QTcF > 500 ms and that of interrupting bedaquiline treatment unnecessarily. We propose ECG monitoring before treatment and at weeks 2, 4, 8, and 12 after starting bedaquiline treatment. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis

Author

Ngwalero, Precious, Brust, James C. M., van Beek, Stijn W., Wasserman, Sean, Maartens, Gary, Meintjes, Graeme, Joubert, Anton, Norman, Jennifer, Castel, Sandra, Gandhi, Neel R., Denti, Paolo, McIlleron, Helen, Svensson, Elin, Wiesner, Lubbe, Ngwalero, Precious, Brust, James C. M., van Beek, Stijn W., Wasserman, Sean, Maartens, Gary, Meintjes, Graeme, Joubert, Anton, Norman, Jennifer, Castel, Sandra, Gandhi, Neel R., Denti, Paolo, McIlleron, Helen, Svensson, Elin, and Wiesner, Lubbe

Abstract

Bedaquiline is recommended for the treatment of all patients with rifampin-resistant tuberculosis (RR-TB). Bedaquiline accumulates within cells, but its intracellular pharmacokinetics have not been characterized, which may have implications for dose optimization. We developed a novel assay using high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) to measure the intracellular concentrations of bedaquiline and its primary metabolite M2 in patients with RR-TB in South Africa. Twenty-one participants were enrolled and underwent sparse sampling of plasma and peripheral blood mononuclear cells (PBMCs) at months 1, 2, and 6 of treatment and at 3 and 6 months after bedaquiline treatment completion. Intensive sampling was performed at month 2. We used noncompartmental analysis to describe plasma and intracellular exposures and a population pharmacokinetic model to explore the relationship between plasma and intracellular pharmacokinetics and the effects of key covariates. Bedaquiline concentrations from month 1 to month 6 of treatment ranged from 94.7 to 2,540 ng/ml in plasma and 16.2 to 5,478 ng/ml in PBMCs, and concentrations of M2 over the 6-month treatment period ranged from 34.3 to 496 ng/ml in plasma and 109.2 to 16,764 ng/ml in PBMCs. Plasma concentrations of bedaquiline were higher than those of M2, but intracellular concentrations of M2 were considerably higher than those of bedaquiline. In the pharmacokinetic modeling, we estimated a linear increase in the intracellular-plasma accumulation ratio for bedaquiline and M2, reaching maximum effect after 2 months of treatment. The typical intracellular-plasma ratios 1 and 2 months after start of treatment were 0.61 (95% confidence interval [CI]: 0.42 to 0.92) and 1.10 (95% CI: 0.74 to 1.63) for bedaquiline and 12.4 (95% CI: 8.8 to 17.8) and 22.2 (95% CI: 15.6 to 32.3) for M2. The intracellular-plasma ratios for both bedaquiline and M2 were decreased by 54% (95% CI: 24 to 72%) in HIV-positive patien

Published
2021
Full Text
View/download PDF

28. Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study

Author

Brust, James C M, primary, Gandhi, Neel R, additional, Wasserman, Sean, additional, Maartens, Gary, additional, Omar, Shaheed V, additional, Ismail, Nazir A, additional, Campbell, Angela, additional, Joseph, Lindsay, additional, Hahn, Alexandria, additional, Allana, Salim, additional, Hernandez-Romieu, Alfonso C, additional, Zhang, Chenshu, additional, Mlisana, Koleka, additional, Viljoen, Charle A, additional, Zalta, Benjamin, additional, Ebrahim, Ismaeel, additional, Franczek, Meghan, additional, Master, Iqbal, additional, Ramangoaela, Limpho, additional, te Riele, Julian, additional, and Meintjes, Graeme, additional

Published
2021
Full Text
View/download PDF

29. Clofazimine pharmacokinetics in patients with TB : dosing implications

Author

Abdelwahab, Mahmoud Tareq, Wasserman, Sean, Brust, James C. M., Gandhi, Neel R., Meintjes, Graeme, Everitt, Daniel, Diacon, Andreas, Dawson, Rodney, Wiesner, Lubbe, Svensson, Elin, Maartens, Gary, Denti, Paolo, Abdelwahab, Mahmoud Tareq, Wasserman, Sean, Brust, James C. M., Gandhi, Neel R., Meintjes, Graeme, Everitt, Daniel, Diacon, Andreas, Dawson, Rodney, Wiesner, Lubbe, Svensson, Elin, Maartens, Gary, and Denti, Paolo

Abstract

Background: Clofazimine is in widespread use as a key component of drug-resistant TB regimens, but the recommended dose is not evidence based. Pharmacokinetic data from relevant patient populations are needed to inform dose optimization. Objectives: To determine clofazimine exposure, evaluate covariate effects on variability, and simulate exposures for different dosing strategies in South African TB patients. Patients and methods: Clinical and pharmacokinetic data were obtained from participants with pulmonary TB enrolled in two studies with intensive and sparse sampling for up to 6 months. Plasma concentrations were measured by LC-MS/MS and interpreted with non-Linear mixed-effects modelling. Body size descriptors and other potential covariates were tested on pharmacokinetic parameters. We simulated different dosing regimens to safely shorten time to average daily concentration above a putative target concentration of 0.25 mg/L. Results: We analysed 1570 clofazimine concentrations from 139 participants; 79 (57%) had drug-resistant TB and 54 (39%) were HIV infected. Clofazimine pharmacokinetics were well characterized by a three-compartment model. Clearance was 11.5 L/h and peripheral volume 10500 L for a typical participant. Lower plasma exposures were observed in women during the first few months of treatment, explained by higher body fat fraction. Model-based simulations estimated that a Loading dose of 200 mg daily for 2 weeks would achieve average daily concentrations above a target efficacy concentration 37 days earlier in a typical TB participant. Conclusions: Clofazimine was widely distributed with a Long elimination half-Life. Disposition was strongly influenced by body fat content, with potential dosing implications for women with TB.

Published
2020
Full Text
View/download PDF

31. Clofazimine pharmacokinetics in patients with TB: dosing implications

Author

Abdelwahab, Mahmoud Tareq, primary, Wasserman, Sean, additional, Brust, James C M, additional, Gandhi, Neel R, additional, Meintjes, Graeme, additional, Everitt, Daniel, additional, Diacon, Andreas, additional, Dawson, Rodney, additional, Wiesner, Lubbe, additional, Svensson, Elin M, additional, Maartens, Gary, additional, and Denti, Paolo, additional

Published
2020
Full Text
View/download PDF

32. Modeling Missing Cases and Transmission Links in Networks of Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa

Author

Nelson, Kristin N, primary, Gandhi, Neel R, additional, Mathema, Barun, additional, Lopman, Benjamin A, additional, Brust, James C M, additional, Auld, Sara C, additional, Ismail, Nazir, additional, Omar, Shaheed Vally, additional, Brown, Tyler S, additional, Allana, Salim, additional, Campbell, Angie, additional, Moodley, Pravi, additional, Mlisana, Koleka, additional, Shah, N Sarita, additional, and Jenness, Samuel M, additional

Published
2020
Full Text
View/download PDF

33. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis

Author

Lan, Zhiyi, primary, Ahmad, Nafees, additional, Baghaei, Parvaneh, additional, Barkane, Linda, additional, Benedetti, Andrea, additional, Brode, Sarah K, additional, Brust, James C M, additional, Campbell, Jonathon R, additional, Chang, Vicky Wai Lai, additional, Falzon, Dennis, additional, Guglielmetti, Lorenzo, additional, Isaakidis, Petros, additional, Kempker, Russell R, additional, Kipiani, Maia, additional, Kuksa, Liga, additional, Lange, Christoph, additional, Laniado-Laborín, Rafael, additional, Nahid, Payam, additional, Rodrigues, Denise, additional, Singla, Rupak, additional, Udwadia, Zarir F, additional, Menzies, Dick, additional, Ahmad, N, additional, Baghaei, P, additional, Barkane, L, additional, Benedetti, A, additional, Brode, SK, additional, Brust, JCM, additional, Campbell, JR, additional, Chang, VWL, additional, Falzon, D, additional, Guglielmetti, L, additional, Isaakidis, P, additional, Kempker, RR, additional, Kipiani, M, additional, Kuksa, L, additional, Lan, Z, additional, Lange, C, additional, Laniado-Laborín, R, additional, Nahid, P, additional, Rodrigues, D, additional, Singla, R, additional, Udwadia, ZF, additional, and Menzies, D, additional

Published
2020
Full Text
View/download PDF

35. Social Mixing and Clinical Features Linked With Transmission in a Network of Extensively Drug-resistant Tuberculosis Cases in KwaZulu-Natal, South Africa

Author

Nelson, Kristin N, primary, Jenness, Samuel M, primary, Mathema, Barun, primary, Lopman, Benjamin A, primary, Auld, Sara C, primary, Shah, N Sarita, primary, Brust, James C M, primary, Ismail, Nazir, primary, Omar, Shaheed Vally, primary, Brown, Tyler S, primary, Allana, Salim, primary, Campbell, Angie, primary, Moodley, Pravi, primary, Mlisana, Koleka, primary, and Gandhi, Neel R, primary

Published
2019
Full Text
View/download PDF

36. Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection

Author

Wasserman, Sean, primary, Denti, Paolo, additional, Brust, James C. M., additional, Abdelwahab, Mahmoud, additional, Hlungulu, Siphokazi, additional, Wiesner, Lubbe, additional, Norman, Jennifer, additional, Sirgel, Frederick A., additional, Warren, Robin M., additional, Esmail, Aliasgar, additional, Dheda, Keertan, additional, Gandhi, Neel R., additional, Meintjes, Graeme, additional, and Maartens, Gary, additional

Published
2019
Full Text
View/download PDF

38. Social Mixing and Clinical Features Linked With Transmission in a Network of Extensively Drug-resistant Tuberculosis Cases in KwaZulu-Natal, South Africa.

Author

Nelson, Kristin N, Jenness, Samuel M, Mathema, Barun, Lopman, Benjamin A, Auld, Sara C, Shah, N Sarita, Brust, James C M, Ismail, Nazir, Omar, Shaheed Vally, Brown, Tyler S, Allana, Salim, Campbell, Angie, Moodley, Pravi, Mlisana, Koleka, and Gandhi, Neel R

Subjects
INFECTIOUS disease transmission, COUGH, METROPOLITAN areas, SPUTUM, SEQUENCE analysis
Abstract

Background Tuberculosis (TB) is the leading infectious cause of death globally, and drug-resistant TB strains pose a serious threat to controlling the global TB epidemic. The clinical features, locations, and social factors driving transmission in settings with high incidences of drug-resistant TB are poorly understood. Methods We measured a network of genomic links using Mycobacterium tuberculosis whole-genome sequences. Results Patients with 2–3 months of cough or who spent time in urban locations were more likely to be linked in the network, while patients with sputum smear–positive disease were less likely to be linked than those with smear-negative disease. Associations persisted using different thresholds to define genomic links and irrespective of assumptions about the direction of transmission. Conclusions Identifying factors that lead to many transmissions, including contact with urban areas, can suggest settings instrumental in transmission and indicate optimal locations and groups to target with interventions. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

40. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

Author

Ahmad, Nafees, primary, Ahuja, Shama D, additional, Akkerman, Onno W, additional, Alffenaar, Jan-Willem C, additional, Anderson, Laura F, additional, Baghaei, Parvaneh, additional, Bang, Didi, additional, Barry, Pennan M, additional, Bastos, Mayara L, additional, Behera, Digamber, additional, Benedetti, Andrea, additional, Bisson, Gregory P, additional, Boeree, Martin J, additional, Bonnet, Maryline, additional, Brode, Sarah K, additional, Brust, James C M, additional, Cai, Ying, additional, Caumes, Eric, additional, Cegielski, J Peter, additional, Centis, Rosella, additional, Chan, Pei-Chun, additional, Chan, Edward D, additional, Chang, Kwok-Chiu, additional, Charles, Macarthur, additional, Cirule, Andra, additional, Dalcolmo, Margareth Pretti, additional, D'Ambrosio, Lia, additional, de Vries, Gerard, additional, Dheda, Keertan, additional, Esmail, Aliasgar, additional, Flood, Jennifer, additional, Fox, Gregory J, additional, Fréchet-Jachym, Mathilde, additional, Fregona, Geisa, additional, Gayoso, Regina, additional, Gegia, Medea, additional, Gler, Maria Tarcela, additional, Gu, Sue, additional, Guglielmetti, Lorenzo, additional, Holtz, Timothy H, additional, Hughes, Jennifer, additional, Isaakidis, Petros, additional, Jarlsberg, Leah, additional, Kempker, Russell R, additional, Keshavjee, Salmaan, additional, Khan, Faiz Ahmad, additional, Kipiani, Maia, additional, Koenig, Serena P, additional, Koh, Won-Jung, additional, Kritski, Afranio, additional, Kuksa, Liga, additional, Kvasnovsky, Charlotte L, additional, Kwak, Nakwon, additional, Lan, Zhiyi, additional, Lange, Christoph, additional, Laniado-Laborín, Rafael, additional, Lee, Myungsun, additional, Leimane, Vaira, additional, Leung, Chi-Chiu, additional, Leung, Eric Chung-Ching, additional, Li, Pei Zhi, additional, Lowenthal, Phil, additional, Maciel, Ethel L, additional, Marks, Suzanne M, additional, Mase, Sundari, additional, Mbuagbaw, Lawrence, additional, Migliori, Giovanni B, additional, Milanov, Vladimir, additional, Miller, Ann C, additional, Mitnick, Carole D, additional, Modongo, Chawangwa, additional, Mohr, Erika, additional, Monedero, Ignacio, additional, Nahid, Payam, additional, Ndjeka, Norbert, additional, O'Donnell, Max R, additional, Padayatchi, Nesri, additional, Palmero, Domingo, additional, Pape, Jean William, additional, Podewils, Laura J, additional, Reynolds, Ian, additional, Riekstina, Vija, additional, Robert, Jérôme, additional, Rodriguez, Maria, additional, Seaworth, Barbara, additional, Seung, Kwonjune J, additional, Schnippel, Kathryn, additional, Shim, Tae Sun, additional, Singla, Rupak, additional, Smith, Sarah E, additional, Sotgiu, Giovanni, additional, Sukhbaatar, Ganzaya, additional, Tabarsi, Payam, additional, Tiberi, Simon, additional, Trajman, Anete, additional, Trieu, Lisa, additional, Udwadia, Zarir F, additional, van der Werf, Tjip S, additional, Veziris, Nicolas, additional, Viiklepp, Piret, additional, Vilbrun, Stalz Charles, additional, Walsh, Kathleen, additional, Westenhouse, Janice, additional, Yew, Wing-Wai, additional, Yim, Jae-Joon, additional, Zetola, Nicola M, additional, Zignol, Matteo, additional, and Menzies, Dick, additional

Published
2018
Full Text
View/download PDF

42. Improved Survival and Cure Rates With Concurrent Treatment for Multidrug-Resistant Tuberculosis–Human Immunodeficiency Virus Coinfection in South Africa

Author

Brust, James C M, primary, Shah, N Sarita, additional, Mlisana, Koleka, additional, Moodley, Pravi, additional, Allana, Salim, additional, Campbell, Angela, additional, Johnson, Brent A, additional, Master, Iqbal, additional, Mthiyane, Thuli, additional, Lachman, Simlatha, additional, Larkan, Lee-Megan, additional, Ning, Yuming, additional, Malik, Amyn, additional, Smith, Jonathan P, additional, and Gandhi, Neel R, additional

Published
2017
Full Text
View/download PDF

43. Spatial distribution of extensively drug-resistant tuberculosis (XDR TB) patients in KwaZulu-Natal, South Africa

Author

Kapwata, Thandi, primary, Morris, Natashia, additional, Campbell, Angela, additional, Mthiyane, Thuli, additional, Mpangase, Primrose, additional, Nelson, Kristin N., additional, Allana, Salim, additional, Brust, James C. M., additional, Moodley, Pravi, additional, Mlisana, Koleka, additional, Gandhi, Neel R., additional, and Shah, N. Sarita, additional

Published
2017
Full Text
View/download PDF

44. Polymorphisms in the vitamin D receptor gene are associated with reduced rate of sputum culture conversion in multidrug-resistant tuberculosis patients in South Africa

Author

Magee, Matthew J., primary, Sun, Yan V., additional, Brust, James C. M., additional, Shah, N. Sarita, additional, Ning, Yuming, additional, Allana, Salim, additional, Campbell, Angela, additional, Hui, Qin, additional, Mlisana, Koleka, additional, Moodley, Pravi, additional, and Gandhi, Neel R., additional

Published
2017
Full Text
View/download PDF

49. pncA Gene Mutations Associated with Pyrazinamide Resistance in Drug-Resistant Tuberculosis, South Africa and Georgia.

Author

Allana, Salim, Shashkina, Elena, Mathema, Barun, Bablishvili, Nino, Tukvadze, Nestani, Shah, N. Sarita, Kempker, Russell R., Blumberg, Henry M., Moodley, Pravi, Mlisana, Koleka, Brust, James C. M., and Gandhi, Neel R.

Subjects
PYRAZINAMIDE, DRUG resistance, TUBERCULOSIS treatment, DRUG use testing, GENETIC polymorphisms, THERAPEUTICS
Abstract

Although pyrazinamide is commonly used for tuberculosis treatment, drug-susceptibility testing is not routinely available. We found polymorphisms in the pncA gene for 70% of multidrug-resistant and 96% of extensively drug-resistant Mycobacterium tuberculosis isolates from South Africa and Georgia. Assessment of pyrazinamide susceptibility may be prudent before using it in regimens for drug-resistant tuberculosis. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results